Get the Stockscreener App
51.35
1.20%
0.61
Gsk Plc Adr stock is traded at $51.35, with a volume of 5.96M.
It is up +1.20% in the last 24 hours and up +0.51% over the past month.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
See More
Previous Close:
$50.74
Open:
$51.395
24h Volume:
5.96M
Relative Volume:
1.49
Market Cap:
$102.84B
Revenue:
$43.93B
Net Income/Loss:
$8.53B
P/E Ratio:
13.43
EPS:
3.824
Net Cash Flow:
$5.74B
1W Performance:
-0.79%
1M Performance:
+0.51%
6M Performance:
+4.48%
1Y Performance:
+34.32%
1-Day Range:
$51.00
$51.56
1-Week Range:
$49.89
$51.83
52-Week Range:
$36.75
$61.70
Gsk Plc Adr Stock (GSK) Company Profile
Name
Gsk Plc Adr
Sector
Industry
Phone
-
Address
-
Compare GSK vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
51.35 | 102.84B | 43.93B | 8.53B | 5.74B | 3.824 |
LLY
Lilly Eli Co
|
1,196.03 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.40 | 634.77B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
259.36 | 458.24B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
131.07 | 323.72B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.01 | 294.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Neutral |
| Jan-06-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-25-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-03-25 | Downgrade | Berenberg | Buy → Hold |
| Apr-15-25 | Initiated | Exane BNP Paribas | Neutral |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-15-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Nov-12-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-24 | Downgrade | UBS | Buy → Neutral |
| May-30-24 | Initiated | Goldman | Neutral |
| Mar-04-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-13-24 | Upgrade | Citigroup | Neutral → Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Jan-03-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Mar-17-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-27-23 | Resumed | Goldman | Buy |
| Jan-03-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-11-22 | Downgrade | UBS | Neutral → Sell |
| Sep-15-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Sep-08-22 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-21-22 | Resumed | Citigroup | Neutral |
| Feb-11-22 | Downgrade | DZ Bank | Buy → Hold |
| Nov-05-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Jun-24-21 | Upgrade | Deutsche Bank | Sell → Hold |
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-04-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-20-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jan-15-21 | Initiated | Deutsche Bank | Hold |
| Nov-02-20 | Upgrade | Liberum | Hold → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Feb-12-20 | Downgrade | Shore Capital | Hold → Sell |
| Jan-16-20 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-19 | Initiated | SVB Leerink | Outperform |
| Nov-21-19 | Upgrade | UBS | Neutral → Buy |
| Oct-11-19 | Upgrade | Cantor Fitzgerald | Hold → Buy |
| Sep-03-19 | Resumed | Citigroup | Neutral |
| Sep-03-19 | Upgrade | Societe Generale | Sell → Buy |
| Aug-13-19 | Resumed | JP Morgan | Neutral |
| Jun-17-19 | Resumed | Morgan Stanley | Underweight |
| Mar-08-19 | Downgrade | Shore Capital | Buy → Hold |
| Feb-22-19 | Downgrade | UBS | Buy → Neutral |
| Jan-14-19 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Aug-30-18 | Downgrade | Liberum | Buy → Hold |
| Apr-04-18 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-22-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-09-18 | Upgrade | Kepler | Reduce → Hold |
View All
Gsk Plc Adr Stock (GSK) Latest News
GSK: Glaxosmithkline plcADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule - Sahm
Free cash flow of GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs – BCBA:GSK.CI - TradingView
PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight - GlobeNewswire Inc.
GSK ends camlipixant programme after CALM-2 miss - grafa.com
Disappointing Data Prompts GSK to Drop Cough Drug Development - Sahm
GSK Stock Quote Price and Forecast - CNN
GSKH ETF Profile: Dividends, Returns (AMEX:GSKH) - TradingView
GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer - TradingView
GSK reports Jemperli rectal cancer trial results - grafa.com
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership - Sahm
As Biopharma Turns to China, ESG Risks and Geopolitics Remain in Focus - Morningstar
Price to earnings forward of GSK plc Sponsored ADR – MUN:GS70 - TradingView
GSKGSK Plc ADR Latest SEC Filings - Finviz
GS70 Forecast — Price Target — Prediction for 2027 - TradingView
Shareholder in GSK (NYSE: GSK) trims voting stake to 4.96% - Stock Titan
GSK to strengthen oncology pipeline with $10.6B Nuvalent buyout - MSN
Price to earnings forward of GSK plc Sponsored ADR – LS:A3DMHS - TradingView
A3DMHS Forecast — Price Target — Prediction for 2027 - TradingView
GSK plc (GSK) Stock Price, News, Quote & History - Yahoo Finance
GSK (GSK) reports major holder crossing 5% voting rights threshold - Stock Titan
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Actuals & Estimates (BCBA:GSKC) - TradingView
Why GSK's Shingrix is reshaping the shingles vaccine market - AD HOC NEWS
GSK PLC (GSK) Stock Price, Trades & News - GuruFocus
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs - Sahm
Here's Our Take On Theravance Biopharma Inc (NASDAQ:TBPH) and GlaxoSmithKline plc (ADR) (NYSE:GSK)'s Latest Submission - Yahoo Finance
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder - TradingView
GSK secures dual US and EU orphan drug status for momelotinib in VEXAS - grafa.com
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal - Sahm
GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent - Sahm
GSK plc stock (GB0009252882): Nuvalent deal sharpens oncology focus - AD HOC NEWS
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout - TradingView
GSK to acquire cancer biotech Nuvalent in $10.6 billion deal - grafa.com
Why is Glaxo (GSK) down 2.1% since last earnings report? - MSN
GSK Bets on Specialty Medicines to Drive Long-Term Revenue Growth - TradingView
Gsk Plc Adr Stock (GSK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.88%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):